PeptiDream and Novartis extend peptide discovery collaboration
Betsy Goodfellow | April 30, 2024 | News story | Research and Development | Novartis, PeptiDream, Pharmacy, collaboration, drug discovery, peptides
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Under the terms of the collaboration PeptiDream will use its Peptide Discovery Platform System (PDPS) technology to ‘identify and optimise novel macrocyclic peptides against targets selected by Novartis for potential conjugation to radionuclides or other applications for both therapeutic and diagnostic purposes’, according to the company’s press release.
This expands upon the two companies’ existing peptide-drug conjugate (PDC) collaboration which began in 2019, following collaborations dating back to 2010.
It is expected that Novartis will pay PeptiDream an upfront payment of $180m, as well as up to $2.71bn in development, regulatory and commercial milestones that have already been determined and tiered royalties on any products resulting from the collaboration.
Patrick C Reid PhD, chief executive officer of PeptiDream, commented: “We are delighted to further expand our long-standing macrocyclic peptide discovery collaboration with Novartis, adding additional peptide RLT and other programmes to our strong partnership. As macrocyclic peptides continue to be the ideal vectors for the targeted deliver of a variety of therapeutic payloads, PeptiDream continues to build an extensive pipeline of partnered as well as internal peptide-conjugate programmes.”
Shiva Malek, global head of oncology research at Novartis, added: “We are enthusiastic about the progress we’ve made with PeptiDream through our long-standing research collaboration and look forward to continuing our work together as we strive to create impactful new therapies for patients. Our expanded partnership reflects our shared commitment to pioneering science that broadens the scope of transformative therapeutic approaches such as RLT.”
Betsy Goodfellow
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
